A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Assess the Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Assess the Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Selurampanel (Primary)
  • Indications Muscle spasticity
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 21 Aug 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 01 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top